Stratec Biomedical AG (ETR:SBS) has been assigned a €62.00 ($72.94) target price by equities research analysts at Warburg Research in a research note issued to investors on Tuesday, July 25th. The firm presently has a “buy” rating on the stock.
Other equities research analysts have also issued reports about the stock. Oddo Securities set a €58.00 ($68.24) target price on shares of Stratec Biomedical AG and gave the stock a “neutral” rating in a research report on Monday, July 24th. Berenberg Bank set a €59.00 ($69.41) target price on shares of Stratec Biomedical AG and gave the stock a “neutral” rating in a research report on Tuesday, July 25th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of €60.00 ($70.59).
Shares of Stratec Biomedical AG (ETR:SBS) opened at 51.022 on Tuesday. The company’s 50-day moving average is €55.16 and its 200-day moving average is €54.35. The stock has a market capitalization of €606.55 million and a P/E ratio of 31.515. Stratec Biomedical AG has a one year low of €41.45 and a one year high of €63.18.
About Stratec Biomedical AG
Stratec Biomedical AG (Stratec) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics.
What are top analysts saying about Stratec Biomedical AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stratec Biomedical AG and related companies.